Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Tenoxicam). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Mobiflex is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage Standard dosage: Except for acute gout, the usual dose is 20 mg once daily, taken at the same time each day. Acute gout: 40 mg once daily for the first two days, then 20 mg once daily for the next five days. Chronic conditions: Tenoxicam starts working early in treatment, with the response building gradually over time. Daily doses above 20 mg should be avoided in chronic conditions, as this raises the risk of side effects without adding meaningful benefit. For patients who need long-term treatment, the dose may later be reduced to 10 mg once daily for maintenance. Special populations: These same dosage guidelines generally apply to elderly patients and to those with kidney or liver disease. No dosage has been established for children and adolescents, as clinical experience in these age groups is lacking.
Side Effects
Based on data from clinical trials involving large numbers of patients, Inoten has proved to be well tolerated at the recommended dose, with the undesirable effects reported usually mild and temporary. In only a small proportion of patients was it necessary to stop treatment because of side effects, and local tolerance of Inoten given by injection was good. Effects occurring in more than 1% of patients include gastric, epigastric and abdominal discomfort, dyspepsia, heartburn and nausea affecting the gastrointestinal tract, along with dizziness and headache affecting the central nervous system. Effects occurring in less than 1% of patients include, in the gastrointestinal tract, constipation, diarrhea, stomatitis, gastritis, vomiting, ulcers and gastrointestinal bleeding including hematemesis and melena; in the central nervous system, fatigue, sleep disturbances, loss of appetite, dry mouth and vertigo; in the skin, itching (also in the anal region after rectal use), redness, rash-like eruptions, rash and urticaria; in the urinary tract and kidneys, a rise in BUN or creatinine and edema; in the liver and biliary tract, raised liver enzyme activity; and in the cardiovascular system, palpitations. Isolated cases, occurring in fewer than 0.01% of patients, include gastrointestinal perforation; visual disturbances affecting the central nervous system; Stevens-Johnson syndrome, Lyell's syndrome, photosensitivity reactions and vasculitis affecting the skin; anemia, agranulocytosis, leukopenia and thrombocytopenia affecting the blood; hypersensitivity reactions such as difficulty breathing, asthma, anaphylaxis and angioedema; elevated blood pressure, seen mainly in patients also taking cardiovascular drugs; and hepatitis affecting the liver and biliary tract.
Cautions & Contraindications
Warnings & Precautions
NSAIDs inhibit renal prostaglandin synthesis and consequently may have an undesirable effect on renal hemodynamics and on salt and water balance. It is necessary to adequately monitor the patient, with special emphasis on cardiac and renal function (BUN, creatinine, development of edema, weight gain, etc.), when giving Inoten to patients with conditions that could increase their risk of developing renal failure, such as pre-existing renal disease, impaired renal function in diabetics, hepatic cirrhosis, congestive heart failure, volume depletion, or concomitant treatment with potentially nephrotoxic drugs, diuretics, and corticosteroids. Inoten inhibits platelet aggregation and may affect hemostasis. Inoten has no significant influence on blood coagulation factors, coagulation time, prothrombin time, or activated thromboplastin time. Patients having coagulation disorders or receiving drug therapy that interferes with hemostasis should, however, be carefully observed when Inoten is administered. Any patient being treated with Inoten who presents with symptoms of gastrointestinal disease should be closely monitored. If peptic ulceration or gastrointestinal bleeding occurs, Inoten should be withdrawn immediately. If severe skin reactions, such as Lyell's syndrome or Stevens-Johnson syndrome, occur, treatment should be discontinued immediately. Adverse eye findings have been reported with Inoten, so ophthalmic evaluation is recommended for patients who develop visual disturbances. Because of the high plasma protein binding of Inoten, caution is required when plasma albumin levels are markedly reduced. As with anti-inflammatory drugs in general, Inoten may mask the usual signs of infection. Inoten tablets should not be given to patients who either dislike or do not tolerate milk products.
Contraindications
Tenoxicam should not be given to anyone who is hypersensitive to it, or who has previously developed asthma, rhinitis, or urticaria after taking aspirin or other NSAIDs. It is also unsuitable for patients with a current or past history of upper gastrointestinal disease, such as gastritis or gastric and duodenal ulcers.